The effects of the subconjunctival injection of bevacizumab (Avastin®) on angiogenesis in the rat cornea
Open Access
- 1 September 2007
- journal article
- Published by FapUNIFESP (SciELO) in Anais da Academia Brasileira de Ciências
- Vol. 79 (3) , 389-394
Abstract
The purpose of this study was to evaluate the effects of the use of the subconjunctival injection of bevacizumab (Avastin®) on angiogenesis in the rat cornea. Corneas of 20 Wistar male rats were cauterized with silver nitrate crystal. Animals were divided in four groups: control group (GC) that received subconjunctivally 0.02 ml of 0.9% saline solution on the day of the lesion; group GO that received subconjunctivally 0.02 ml of bevacizumab just after the lesion; group G3 that received bevacizumab on day 3 and group G5 that received bevacizumab on day 5 after lesion. Animals were euthanized on day 7. The newly formed vessels were quantified after China Ink perfusion and photographs were obtained and analyzed in a computerized system (Image Pro-Plus®). In the control group, neovascularization covered 53.56% ± 15.11 (mean ± SD) of the corneal surface, compared with 35.57% ± 18.80 (mean ± SD) in the G0 group, 30.60%±11.82 (mean±SD) in the G3 and 35.86%±0.07 (mean±SD) in the G5. The results showed an inhibition of angiogenesis when the control group was compared with all treated groups. These results suggest that subconjunctival injection of bevacizumab is able to inhibit corneal angiogenesis independently of the day of treatment.Keywords
This publication has 26 references indexed in Scilit:
- SAFETY OF INTRAVITREAL INJECTION OF BEVACIZUMAB IN RABBIT EYESRetina, 2006
- Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic RetinopathyOphthalmology, 2006
- Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular DegenerationOphthalmology, 2006
- REGRESSION OF RETINAL AND IRIS NEOVASCULARIZATION AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENTRetina, 2006
- Pegaptanib for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2004
- Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancerTechniques in Coloproctology, 2004
- Vascular endothelial growth factor (VEGF) and its receptor VEGFR‐2 in the regulation of corneal neovascularization and wound healingActa Ophthalmologica Scandinavica, 2004
- Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularizationExperimental Eye Research, 2004
- Inhibition of interleukin‐1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritisArthritis & Rheumatism, 2002
- Corneal neovascularizationCurrent Opinion in Ophthalmology, 2001